BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Becton, Dickinson And Company (BDX) Designated One Of The Best Workplaces For Commuters(SM) By U.S. EPA And DOT


10/19/2005 5:11:31 PM

SAN JOSE, Calif., July 27 /PRNewswire-FirstCall/ -- BD (Becton, Dickinson and Company) today announced that its BD Biosciences Pharmingen unit has been designated one of the Best Workplaces for Commuters(SM) by the U.S. Environmental Protection Agency (EPA) and U.S. Department of Transportation (DOT).

Best Workplaces for Commuters(SM), a voluntary partnership program designed to cut traffic congestion and traffic-related air pollution, recognizes employers that provide environmentally friendly commuter benefits to employees. Offering these commuter benefits identifies BD Biosciences as an organization committed to reducing pollution, commuting costs, traffic congestion, and employee stress caused by single-occupant vehicle commuting.

As part of a comprehensive commuter benefits program, BD Biosciences Pharmingen offers commuting options and support services such as a web-based program and commuting information, monthly participation incentives, subsidized transit fares, a guaranteed emergency ride home program, carpool matching, and a commuting awards program.

"We are proud to make this commitment to our employees and to the environment," said Kip Miller, Vice President and General Manager, BD Biosciences Pharmingen. "The Best Workplaces for Commuters(SM) program is an example of BD's commitment to a clean environment and supports our corporate purpose: helping all people live healthy lives."

According to Margo Oge, EPA director of the Office of Transportation and Air Quality, the effects of incentive programs like Best Workplaces for Commuters(SM) can be dramatic. "If just half of all U.S. employees were covered under these commuter benefits," said Oge, "traffic and air pollution could be cut by the equivalent of taking 15 million cars off the road every year, saving American workers about $12 billion in fuel costs. That's both cleaner air and real savings for families."

BD is a medical technology company that serves healthcare institutions, life science researchers, clinical laboratories, industry, and the general public. BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. For the fiscal year ended September 30, 2003, BD reported total revenues of $4.528 billion.

Best Workplaces for Commuters(SM) (http://www.bwc.gov/) is a public-private partnership developed by the EPA and DOT. EPA and DOT have established a voluntary National Standard of Excellence for employer-provided commuter benefits. The program challenges employers across the country to voluntarily meet the National Standard of Excellence.

This press release may contain certain forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, products and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; changes in interest or foreign currency exchange rates; changes in BD's sales volume and product mix; BD's ability to achieve its cost savings objectives; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; increases in energy costs; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; uncertainties of litigation; and changes in healthcare or other governmental regulation; issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements.

BD, BD logo, and all other trademarks are the property of Becton, Dickinson and Company.

BD (Becton, Dickinson and Company)

CONTACT: Lisa English, PhD, BD Biosciences, Strategic Communications,+1-408-954-2339, Lisa_English@bd.com; Bob Schultze, BD Biosciences Pharmingen,Facility Operations, +1-858-812-8850, Bob_Schultze@bd.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->